Approved HIV Drugs
Approved HIV Drugs
CROI 2011: Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz
- Details
- Category: Approved HIV Drugs
- Published on Friday, 18 March 2011 00:25
- Written by Matt Sharp
HIV positive people who use antiretroviral regimens containing the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (TMC278) saw smaller changes in their vitamin D levels and were less likely to develop severe deficiency than people taking efavirenz, according to a presentation at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) this month in Boston. 
Once-daily Raltegravir Found Less Effective than Twice-Daily Dosing
- Details
- Category: Approved HIV Drugs
- Published on Monday, 07 March 2011 20:40
- Written by Liz Highleyman
In treatment-naive HIV patients the integrase inhibitor raltegravir (Isentress) taken once-daily was inferior to twice-daily dosing, according to findings from the QDMRK study presented this week at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston. The difference in efficacy was especially pronounced among people with low baseline viral load.
Twice-daily Raltegravir Works Better than Once-daily for First-line HIV Treatment
- Details
- Category: Approved HIV Drugs
- Published on Friday, 03 December 2010 13:38
- Written by Merck
Merck announced this week that it has halted a Phase 3 study of once-daily administration of its integrase inhibitor raltegravir (Isentress), after 48-week data showed that twice-daily dosing did a better job of maintaining HIV suppression in treatment-naive patients. The non-inferiority of twice-daily dosing was particularly evident in people who were starting antiretroviral therapy (ART) for the first time with a high viral load.
ViiV Joins Welvista Program for People on ADAP Waiting Lists
- Details
- Category: Approved HIV Drugs
- Published on Friday, 07 January 2011 12:55
- Written by ViiV Healthcare
ViiV Healthcare -- the HIV specialty company formed by GlaxoSmithKline and Pfizer -- announced this week that it will now participate in the Welvista program, a collaborative initiative to provide antiretroviral medications to low-income people on AIDS Drug Assistance Program (ADAP) waiting lists, which are growing in several states in the wake of the ongoing financial crisis.
Merck Expands Co-pay Assistance Program for Raltegravir (Isentress)
- Details
- Category: HIV Treatment
- Published on Friday, 29 October 2010 14:17
- Written by Merck
Merck announced last week that it has expanded its co-pay assistance program for the integrase inhibitor raltegravir (Isentress). The program will now offer assistance for eligible patients with private insurance who have out-of-pocket copays.
More Articles...
- Phase 2 Trial Tests Intensified Antiretroviral Therapy plus Interleukin-7 for HIV Eradication
- ViiV Healthcare Expands Patient Assistance Program
- GRACE Trial Finds Women Respond as Well as Men to HIV Treatment, but More Likely to Stop Therapy
- Rilpivirine Failure Linked to High Viral Load and Poor Adherence
Web Design and Development by